Welltory Highlights Growing Pharma Demand for Wearable-Driven Clinical Data

According to a recent LinkedIn post from Welltory, company executive Zoia Andreeva attended a Boston networking event focused on healthcare, pharma, and business, where discussions emphasized the rapid adoption of wearable technology in the pharmaceutical sector. The post cites industry commentary suggesting wearable-derived endpoints are moving from exploratory to primary roles in clinical trial protocols, with the first drug approval supported by a digital primary endpoint anticipated within two to three years.

The post references projections that the global wearable healthcare market could reach $186 billion by 2030, up from $24.6 billion in 2018, framing this as a structural shift in how pharma gathers patient data. It highlights examples such as Merck’s use of sensor-based tools to collect continuous, real-world patient data outside traditional clinical settings.

Welltory’s LinkedIn post positions the company as operating at the intersection of continuous monitoring and clinical-grade data, pointing to 17 million-plus installs, integrations with more than 1,000 devices, and AI-driven health insights. The post also indicates that discussions with pharmaceutical companies and contract research organizations are becoming “very real, very fast,” suggesting growing commercial dialogue around incorporating Welltory’s capabilities into clinical research workflows.

For investors, the post implies potential upside for Welltory if pharma’s pivot to wearable-enabled trials accelerates and translates into formal partnerships or recurring revenue streams. It also underscores intensifying competition in digital health and wearable data, where scale in user base, device integrations, and validated clinical use cases may become key differentiators influencing valuation and strategic positioning.